Navigation Links
Common gene variants influence risk factor for sudden cardiac death
Date:3/23/2009

A new study has identified several common genetic variants related to a risk factor for sudden cardiac death. The report receiving early online release in the journal Nature Genetics identifies variants in genes, some known and some newly discovered, that influence the QT interval measured on the electrocardiogram (EKG) performed routinely in doctors' offices. These findings could eventually help to prevent sudden cardiac death and arrhythmia by limiting the use of medications that affect QT interval in people with these variants.

The QT interval is the time from the beginning of electrical activation of the heart to the end of electrical relaxation. "It is well established that prolongation of the QT interval in the general population is a potent and heritable risk factor for sudden death," said Christopher Newton-Cheh, MD, MPH, of the Massachusetts General Hospital (MGH) Center for Human Genetic Research and Cardiovascular Research Center (CVRC) and lead author of the Nature Genetics article. "In addition, QT prolongation results from medications leading to drug-induced cardiac arrhythmias and sudden death. This is a cardiotoxic side effect of scores of medications in widespread use and has been a major barrier to the development of novel drugs. From studies of families with congenital long-QT syndrome, we know that rare mutations with strong effects on ion channel function lead to QT prolongation and sudden death. But the common genetic basis for QT prolongation has been very difficult to establish."

To search for QT-associated variants, the investigators formed the QTGEN consortium, assembling more than 13,000 individuals from three studies including the National Heart, Lung and Blood Institute's and Boston University's Framingham Heart Study, the Rotterdam Study and the Cardiovascular Health Study. All individuals had undergone testing of hundreds of thousands of common gene variations called single-nucleotide polymorphisms (SNPs).

By pooling results from the three studies, investigators identified 14 common variants in 10 different gene regions (some regions had more than one variant) that were related to QT interval duration. A separate companion paper from the QTSCD consortium in the same issue of Nature Genetics led by Arne Pfeufer, MD, of the Technical University of Munich and Aravinda Chakravarti, PhD, Johns Hopkins University School of Medicine included more than 15,000 individuals from Europe and the US. This independent study strongly confirmed 12 out of 14 of the QTGEN variants and identified two additional gene regions. "We were very reassured to see such strong replication in two independent studies" said Newton-Cheh.

The QTGEN investigators examined the effect of a genotype score comprised of all 14 variants tested together. The top 20 percent of the population with the highest genotype scores had 160 to 210 percent higher risk of prolonged QT interval compared to the 20 percent of the population with the lowest scores. They also had around 10 millisecond longer QT intervals, which is approximately the degree of QT interval prolongation observed for some drugs pulled from the market for arrhythmias.

"While it is commonly a combination of risk factors that contributes to drug-induced arrhythmias such as older age, female sex, use of other medications, or heart disease it is certainly possible that common genetic variants will add incrementally to risk prediction," said Newton-Cheh. "It's currently premature to advocate screening gene variants for risk assessment, but someday it may be possible to identify individuals who are at particularly high risk and should avoid such medications."

Newton-Cheh adds, "It's likely that many more genes will be found to contribute to changes in QT interval, and the real challenge will be understanding the mechanism behind their effects. Five of the gene regions we identified had never before been implicated in QT interval physiology and these genetic observations may thus provide key insights into normal and abnormal human biology." He is an assistant professor of Medicine at Harvard Medical School.


'/>"/>

Contact: Jennifer Gundersen
jgundersen1@partners.org
617-724-6433
Massachusetts General Hospital
Source:Eurekalert

Related biology news :

1. Catching the common cold virus genome
2. Computer superpower strengthens attempts to combat common diseases
3. Common gene variants increase risk of hypertension, may lead to new therapies
4. New vaccine developed for preventing uncommon cold virus
5. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
6. Common soil mineral degrades the nearly indestructible prion
7. Scientists uncover evolutionary keys to common birth disorders
8. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
9. Common food additive found to increase risk and speed spread of lung cancer
10. Hairspray is linked to common genital birth defect, says study
11. GUMC researchers hone in on new strategy to treat common infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... ... ... DuPont Industrial Biosciences (DuPont) and Archer Daniels Midland Company ... Platts Global Energy for their platform technology to produce a revolutionary biobased ... Platts Global Energy Awards, held in New York on Thursday, Dec. 8. , ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
(Date:12/8/2016)... Medical Incorporated ("OncoSec") (NASDAQ: ONCS ), ... announced financial results for the fiscal first quarter ... our commitment to address an unmet medical need ... with the early clinical response data presented from ... on advancing our lead program – ImmunoPulse® IL-12 ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
Breaking Biology Technology: